Merck

Merck operates a complex set of corporate venture and strategic capital vehicles, including Merck Global Health Innovation Fund and the company’s broader external innovation engagements, with the linked URL pointing to the Global Health Innovation team. Treat Merck as a strategic biopharma partner rather than a generalist financial fund. Stage focus runs from Series A through later rounds, with checks typically in the $5M to $20M range and the capacity to participate as a meaningful strategic syndicate member. Healthcare exposure is exclusive and concentrated in digital health, real-world data, AI applied to drug development, and selectively therapeutics and devices that align with Merck’s core franchises in oncology, vaccines, infectious disease, and chronic care. Physician founders building AI for drug development, real-world evidence platforms, patient engagement tools with pharma alignment, or therapeutic adjacencies are the right profile. Founders building consumer wellness brands or unrelated enterprise software will not find a strategic fit. Geographic posture is global. The realistic entry path is engagement through Merck’s external innovation, business development, or strategic capital teams or via a Merck business unit sponsor; warm introductions from co-investing biotech VCs accelerate the process. Founders should arrive prepared for strategic-alignment diligence and engage independent counsel given the complexity of pharma CVC structures. Treat Merck as a strategic late-Series A partner that brings deep pharma insight and commercial validation.